Duchenne News Tags: FibroGen

August 30, 2023
FibroGen announces topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne.
June 7, 2023
FibroGen announces topline data from the Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne.

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA